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In the  next  20 years,  it is  expected  that  70%  of  incident  cancers  will be diagnosed  in the  developing
world. There  exist  very  few models  of  cancer  care  delivery  in  resource  constrained  settings.  We present
a model  of  cancer  care  delivery  that  developed  as a result  of a multi-institutional  collaboration  between
high-income  country  academic  medical  centers  and  a Kenyan  medical  school  and  governmental  referral
hospital.  Based  on the  infrastructure  provided  by a  successful  HIV  care  program,  AMPATH-Oncology
presently  offers  a range  of clinical  services  across  the continuum  of  care,  including  cervical  cancer  andenya
nternational
ealth care
reatment
IV/AIDS
rogram development
breast  cancer  screening,  palliative  care,  and  oncology  clinics  in  pediatric,  adult,  and  gynecology  oncology.
This  program  grew  from  346  patient  visits  amongst  a few dozen  patients  in  2004  to  over  30,000  visits
by  2012  between  screening  programs  and  treatment  programs.  This paper  describes  the  development  of
the program  over  a 7-year  period.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.esearch
. Cancer in the developing world
In 2008, the American Cancer Society estimated that 56% of
ncident cases and 64% of deaths due to cancer occurred in low-
nd middle-income countries (LMCs) [1]. Combined, HIV/AIDS,
uberculosis, and malaria account for fewer deaths in the devel-
ping world than does cancer [2]. Because of industrialization, the
ncroachment of developed world habits (smoking, poor diet), and
emographic shifts (population aging), within two  decades 70% of
ll incident cancers globally will occur in LMCs [3–5]. Cancer mor-
ality in developing countries is as high as 80% (compared to 30%
n High Income Countries), ensuring that cancer will continue to
ove up the rankings as a cause of death in these settings [6].
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Open access under CC BY-NC-ND lThus, LMC  healthcare systems, already underfunded and designed
to handle only acute illness and injury, are woefully underequipped,
ill-designed, and under-staffed for dealing effectively with the rise
in chronic diseases [7]. Models to optimize the delivery of can-
cer care in under-resourced environments must be developed to
address this impending global health care crisis.
The global health community has not been ignoring the
health threat cancer poses in developing countries. A number of
multi-lateral organizations have adopted resolutions or written
white-papers on this topic [5,8–11]. Some groups have presented
high-level guidance documents for governments, which have
common themes: national cancer registry systems; prevention;
screening; treatment; palliative care; and development of can-
cer research agendas and investment in training the workforce
to address the demands of both research and clinical care. On
the other hand, only a few groups have offered more pragmatic
guidance in actual on-ground implementation of cancer care – the
outstanding example being the Breast Health Global Initiative’s
(BHGI) ‘resource-stratiﬁed matrix guidelines’ [12]. These guidelines
divide healthcare systems into 4 economic strata and then present
resource-appropriate recommendations for screening, diagnosis,
icense.
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Table 1
Summary of “Policy Brief on the Situational Analysis of Cancer in Kenya” [46].
National cancer plan No
Cancer registry Kenya Medical Research Insititute (KeMRI)
Moi  Teaching and Referral Hospital
Radiation units in public sector 2 Cobalt-60 Units
National screening programs None
Radiation oncologists 4–5a
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Table 2
Demographics and health-related indicators for Kenya.
Population 37 million [47]
GDP per capita US$ 760 [47]
Population living in rural areas 78% [47]
Infant mortality 55/1000 live births [47]
Life expectancy 54 years [47]
Total national budget dedicated to health 8.4% [48]Oncologists 3–4a
a Variability reﬂective of discrepancies in the original report.
nd treatment of breast cancer. The BHGI recommendations, as
ell as those of CanTreat, also have common themes: affordable,
easible treatment regimens; the imperative to establish cancer
reatment and the need to develop novel approaches to delivery;
he need to start these programs now, to build infrastructure suf-
cient to meet the near-term needs for cancer care in LMCs [13].
owever, as invaluable as these guideline and recommendations
re, implementation has lagged, so there is limited documentation
f successful models of resource-appropriate cancer care collabora-
ion between high-income countries and low- and middle-income
ountries (HC–LMC collaborations) in the literature.
The program descriptors and documentation of programmatic
volution in pediatric oncology, mainly from the Monzas Interna-
ional School of Pediatric Hematology/Oncology (MISPHO) and the
t. Jude International Outreach Program, (IOP), form the bulk of
he published literature [14–19]. More recently, descriptors of the
rocess and implementation of creating a breast-speciﬁc cancer
are delivery system have been published [20]. These publications
ffer insight into the logistics of program development in resource-
onstrained settings, the use of outcomes data to improve care
elivery, and the critical role of understanding the local constraints
nd feasibility of care delivery and the unique solutions that are
reated to solve these issues. In addition literature is developing
n the ﬁeld of cervical cancer screening in LMCs, primarily out of
ndia, South Africa and Zambia [21,22]. However, this literature is
imited in its scope, focusing on either age-speciﬁc populations, or
n disease-speciﬁc populations – and thus there is a gap in the lit-
rature on the implementation of comprehensive cancer control
rograms in the developing world. To redress this gap, we offer a
escription of the evolution of a relatively comprehensive cancer
are program in Western Kenya, in the hope that it can help others
s they create similar programs in similar settings.
. The setting: Western Kenya and AMPATH
There is minimal infrastructure for cancer care in Kenya. Table 1
ummarizes a recent report by the Kenyan government on cancer
are. Beyond these basic numbers, cancer care is largely inaccessi-
le due to geography, limited resources, or cost. Patients in need
f radiation in Western Kenya frequently have earliest available
ppointments 3 to 6 months in the future at facilities 4–6 h away
n Nairobi, cancer drugs are frequently unavailable in governmen-
al hospitals, and have limited availability on the open market, the
osts of transport, chemotherapy, and radiation therapy often ren-
er these services unobtainable.
To contextualize cancer care in Kenya, Table 2 presents basic
emographics and health related indicators for Kenya. Additionally,
here is a national health insurance schema, the National Health
nsurance Fund (NHIF), which covers a substantial portion of in-
atient hospital fees in governmental hospitals. However, this is
nderutilized – in spite of enrollment fees ranging from US$2 to
S$25 monthly only 2.7 million (less than 10% of the popula-
ion) are enrolled [23,24]. Western Kenya, with a population of
0 million, is served by Kenya’s second national referral center,
oi  Teaching and Referral Hospital (MTRH), which has 700 bedsGovernment expenditure annually on health
per capita
US$ 8.30 [2]
(frequently shared between two patients), and in 2010 had more
than 37,000 admissions, and 200,000 outpatient clinic visits.
AMPATH, the Academic Model Providing Access to Healthcare,
was created in 2001 through collaboration between Moi University
School of Medicine (MU), MTRH, and a consortium of North Amer-
ican academic medical centers to increase access to anti-retroviral
drugs for HIV-positive patients in Western Kenya [25–27]. Serving
a catchment of 2 million with over 100 clinics ranging from rel-
atively full service facilities (i.e. governmental District Hospitals),
with physical buildings, reliable electricity, and in-house labora-
tory services to basic facilities relying on tented clinics or makeshift
buildings, AMPATH presently has over 160,000 patients enrolled
in its HIV care program. Supporting this clinical care and research
enterprise are: an NIH-certiﬁed grants management ofﬁce; the
AMPATH Reference Lab, a WHO  certiﬁed TB reference lab, a Good
Clinical and Laboratory Practices (GCLP) and ISO 9000 certiﬁed
laboratory with capability for routine clinical labs; and, an open-
source electronic medical record system, the AMPATH Medical
Records System (AMRS) [28–31]. Growing from its original mission
this organization has expanded its mission to encompass primary
health care and chronic disease management. AMPATH-Oncology
developed out of this infrastructure as a result of the demands of
AMPATH clinicians for services for their cancer patients.
3. AMPATH-Oncology
AMPATH-Oncology developed from the platform of this HIV-
care program to address the care of cancer patients, for whom there
were limited treatment options available. AMPATH-Oncology has
evolved in 4 separate periods, driven by available resources and
clinical demands. The ﬁrst services to develop were in pediatric
oncology, which transitioned into care for AIDS-related malig-
nancy, then to broad-based cancer treatment services, and most
recently, a formally structured model for rationed care commen-
surate with the resource constraints and population burden of
western Kenya. Table 3 presents the evolution of services within
AMPATH-Oncology, the difﬁculties encountered while implemen-
ting changes, and the major investments in terms of programmatic
funding during each of these 4 periods: pre-2005 (Period 1);
2005–2008 (Period 2); 2008–2010 (Period 3); and, 2010–present
(Period 4). Table 4 presents the clinical care team, the capacity
building efforts during each period, the evolution of clinical ser-
vices, clinical volume, and total operational budget.
We believe AMPATH-Oncology represents a uniquely compre-
hensive approach to cancer care delivery in resource-constrained
settings. The evolution of AMPATH-Oncology documents a planned,
step-wise progression of services, as described by MISPHO and
BHGI, balanced against the immediate clinical needs on-ground
[19,32]. AMPATH-Oncology carries forward the guiding princi-
ples of USAID-AMPATH, principles which allowed this program to
develop into one of the largest and most comprehensive HIV/AIDS
treatment programs in sub-Saharan Africa. These principles include
involvement of Kenyan colleagues in a true partnership, in terms
of program ownership, the engagement of the key local repre-
sentatives of the government of Kenya in shaping the program,
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Table 3
Evolution of oncology services and challenges for healthcare delivery over time.
Period Impetus for change Challenges encountered Costs
1 (pre-2005) Children with curable cancer without
access to care
• Ad hoc therapeutic approach due to limited prior
exposure to cancer care amongst clinicians
•  Small clinical team facilitated uniformity in care
protocols
•  Limited access to chemotherapeutics
• Chemotherapy
• Clinician time
2  (2005–08) HIV-positive patients dying in spite of
access to anti-retrovirals
• 1st-line protocols for HIV-associated cancers, but
ad hoc therapeutic approaches
• Increased referral for non-HIV-associated cancers
due to lack of access to any other cancer services
• Increased access to chemotherapy as program
began purchasing directly from suppliers in bulk
• Chemotherapy
• Clinician time
• Clinician training
• Consumables associated with cancer
treatment and screening services
•  Transportation to remote clinics
3  (2008–10) Cancer patients without access to
cancer care presenting to
HIV-malignancy clinics
• Creation of the Department of Haematology and
Oncology in MTRH
• Continued increases in referral for patients with
cancer
•  Expansion of services preceding protocol
development led to increase in ad hoc therapeutic
approaches
•  Increased clinical volume exposed lack of
training amongst clinical staff
• Chemotherapy
• Clinician training
• Consumables associated with cancer
treatment and screening services
•  Transportation to remote clinics
4  (2010–present) Clinical volume exceeding available
resources
• Continued increases in patient volume
threatened to overwhelm available resources
• Recognition that many patients present with
disease for which chemotherapy will not beneﬁt
•  Lack of palliative care services highlighted
g, wit
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nnel
• Chemotherapy
• Clinician training
• Consumables associated with cancer
treatment and screening services
•  Transportation to remote clinics
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 development agenda which long-term sustainability a major
river of decisions, and ﬁnally, an explicit fostering of research to
mprove our understanding of disease, program implementation,
nd improve care from the outset. This balance within AMPATH-
ncology results in a program with truly shared ownership, in
hich Kenyan clinicians have equal investment in the program
s the non-Kenyan physicians. This shared ownership ensures not
nly long-term stability to this program, but also lends ﬂexibility
n addressing the immediate needs of the community in Kenya.
An excellent example of the ﬂexibility inherent in this collab-
ration is the transition from period 3 to 4, driven by several
acts apparent to clinicians on the ground: ﬁrst, many patients
resented in late stages of cancer, with death imminent; second,
ased on very limited supplies of chemotherapy and the cost to
he patient, many patients did not have a meaningful therapeu-
ic beneﬁt; and third, the programmatic budget would soon be
verwhelmed by providing free chemotherapy to the rapidly rising
atient population. Therefore, it became apparent that the human-
stic desire to help all patients presenting to AMPATH-Oncology
ould have to be tempered with approaches to care based on local
resentations, expected response rates, active attempts at down-
taging, and offering patients therapeutic alternatives to palliative
hemotherapy. This led to expert-led reviews balancing literature-
ased expectations and local experience to rank order cancers seen
ithin AMPATH-Oncology, similar to the process described by the
HO  [33]. This rank-order was then used to divide commonly
bserved cancers into three categories: curable or high expected
esponse and clinical beneﬁt; expected moderate rate of response
nd clinical beneﬁt from treatment; and then presentations and
isease to which we expected minimal response rates or clinical
eneﬁts. For the last category of disease, it was  determined that
alliative care was the best treatment option. For the former two
ategories, locally-feasible treatment algorithms and chemother-
py protocols were implemented with targeted supportive care, in
 process similar to those described by MISPHO [34].
Further, AMPATH-Oncology’s approach has led to unplanned
eneﬁts – while not explicitly planned, the initial request byh training and explicit care
onable solution to lack of
• Development of pathology resources
•  Expansion of screening services
Kenyan clinicians to develop a cancer treatment program led to
increased enthusiasm for development of screening programs.
Various authors have commented that screening efforts in LMCs
without treatment opportunities suffer from low engagement
because of the pervasive sense that screening simply informs the
patient earlier of a hopeless situation, thus subsequent follow-up
is poor [32]. In the context of a successful treatment programs
breast and cervical cancer screening can translate into reductions
in mortality.
A  unique and distinguishing characteristic of AMPATH-
Oncology is the multi-institutional partnerships representing
academic institutions from the United States, Canada, and Europe
collaborating with MTRH and AMPATH. AMPATH-Oncology’s
organic development process has the advantage of facilitating
collaborative approach, in which clinicians and scientists from
high-income countries (HCs) are challenged to ﬁnd solutions for
clinical needs deﬁned by their LMC  colleagues. These solutions
evolve through a dynamic process matching the content expertise
from HCs with process expertise of the LMCs. Content expertise
refers to an understanding of the current evidence based standard
of care, whereas process expertise refers to the understanding of
the system constraints of LMCs and the potential local solutions to
approximate the HC standards. Similar processes have been suc-
cessfully used by the various pediatric oncology groups [15,18,34].
The potential weakness to this approach is the inherent reac-
tive nature to programmatic development – programmatic change
is driven by shifting clinical demands, therefore infrastructure to
support the evolving clinical mission of AMPATH-Oncology lags
behind program goals and implementation. This risk can be miti-
gated through early adoption of clinical documentation, which can
be used in post hoc quality assessment and improvement efforts
[18,35]. This can be accomplished either via a pre-existing compre-
hensive clinical records system, or more practically, a minimum set
of key indicators (a minimum dataset) that can be used in a step-
wise evaluation and then subsequent addition of new indicators
can allow for progressive expansion of clinical data tracking and
treatment guidelines.
e28
R
.M
.
 Strother
 et
 al.
 /
 Journal
 of
 Cancer
 Policy
 1 (2013) e25– e30
Table 4
Capacity building and ﬁnancial burden for AMPATH-Oncology over time.
Period Personnel Capacity built Services offered (additive to previous period) Approximate patients by
service/year
Budget (estimated
per year, US$)
1 (pre-2005) • 1 Physician
• 1 Nursea
• Established clinical registry for pediatric cancers
•  Developed space within MTRH for in-patient pediatric
oncology service
• In-patient pediatric oncology care
• Out-patient pediatric oncology care
• Pediatric oncology <50 N/Ab
2 (2005–08) • 3 Physicians
• 2 Nursesa
• Development of basic treatment protocols for
AIDS-associated cancers
•  Re-investment in Eldoret cancer registry
•  Development of cervical cancer screening and dysplasia
treatment
• Outpatient HIV malignancy service (MTRH and
remote sites)
• Pediatric oncology <50 $50,000
•  HIV oncology <200
3  (2008–10) • 3 Physicians
• 1 Medical ofﬁcer
• 4 Nursesa
• 1 Pharmacy
technician
• Established outpatient cancer care in MTRH
•  Trained nurses and pharmacy staff in chemotherapy
safety and administration
• Creation of a oncology pharmacy
• Establishing a multi-disciplinary tumor board
•  Developed resource-feasible treatment algorithms for
pediatric oncology
• Adult outpatient chemotherapy service
•  In-patient adult oncology consult service
•  Cervical cancer screening
• Pediatric oncology 50–100 $250,000
•  Adult oncology 600
•  Cervical screening 300
•  In-patient
consultation
200
4  (2010–present) • 3 Physicians
• 2 Medical ofﬁcers
• 4 Clinical ofﬁcers
• 6 Nursesa
• 1 Pharmacist
• 3 Pharmacy
technicians
• 3 Data staff
• 4 Research staff
• Developed resource-feasible treatment algorithms for all
clinical services
• Developed an immunohistochemistry section with
pathology
•  Trained nurses in clinical breast exam and “screen and
treat” cervical screening program
•  Trained gynecologists in radical hysterectomy
•  Expansion of the electronic medical record to include
medical oncology
• Established a gynecologic oncology fellowship with 2
fellows in training program, led by University of Toronto
• Gynecology oncology clinic
• Scale up cervical cancer screening
• Breast screening clinic
• Palliative care clinic and inpatient service
• Palliative care day care services
• Immunohistochemistry for ER/PR and lymphoma
• Multiple myeloma clinic
• Sickle cell program
• Hemophilia clinic
• Pediatric oncology 250 $750,000
•  Medical oncology 4000
•  Gynecology oncology 230
•  Cervical screening 9000
•  Breast screening 2800
•  In-patient
consultation
1200
a Nursing is supplemented on high clinical volume days by quasi-volunteer nurses, who have received training in chemotherapy safety and administration.
b During this period, Non-Kenyan AMPATH-Oncology was not involved.
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Another strength of the AMPATH-Oncology approach has been
arly incorporation of research into the clinical mission. There are
inimal data to inform clinical decisions in cancer medicine in
eveloping world settings. Given the challenging practice envi-
onment of Kenya, the utilization of protocols developed in HCs,
nd the minimal available outcomes data in LMC  populations,
horter implementation-evaluation timelines could lead to more
ost-efﬁcient treatment with better outcomes [35–41]. An exam-
le of the relatively immediate turn-around of research into clinical
ractice was the creation of the cervical cancer screening pro-
ram. Under the funding from a Fogarty International Center AITRP
rant, a pilot project comparing visual inspection under acetic acid
VIA) to Papanicolaou smear for screening for cervical cancer was
ompleted. This led to the establishment of a VIA-based screening
ervice, and through donations, the equipment and training for
he performance of colposcopy and LEEP for suspicions lesions
ere instituted [42]. At this time AMPATH-Oncology has active
esearch agendas in epidemiology [43], care delivery [44,45], and
rug safety, in addition to clinical trials evaluating therapeutic efﬁ-
acy. AMPATH-Oncology works with the network of researchers
mongst the collaborating North American institutions, as well as
ith outside cooperative groups such as the AIDS Malignancy Con-
ortium and the AIDS Clinical Trials Group.
Finally, the critical component to stemming the tide from the
normous impending burden of cancer is developing an adequately
rained workforce. The number of well-trained Kenyans in the var-
ous disciplines of cancer care – from pathology, medical, surgical,
adiation oncology and nursing – remains woefully underpowered.
rograms such as AMPATH-Oncology build a critical bridge to
eginning to redress this deﬁciency, by linking the subject expertise
f the developed world with the on-ground experience of Kenyan
linicians, ensuring that approaches to care are both practically
pplicable and sustainable.
. Conclusion
The health problems and existing healthcare in LMCs are het-
rogeneous, and therefore no one strategy will ﬁt all low income
ountries. However, successful models for treatment and preven-
ion of HIV/AIDS in Sub-Saharan Africa offer a viable foundation
n which to build other aspects of essential healthcare infrastruc-
ure in LMCs. It is critical that multiple strategic approaches to
mproving cancer care outcomes are explored and validated to
over the needs of multiple low/middle income settings, including
he expansion of the workforce [38]. At present, AMPATH-Oncology
epresents one of the few multi-institutional collaborations creat-
ng a near-comprehensive cancer care program for pediatric and
dult cancers. This platform will allow for unique insight into can-
er care delivery, cancer care cost effectiveness analyses, cancer
pidemiology, and locally relevant translational research.
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